Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.00    -0.50 (-0.73%)
Bid:
67.00
Ask:
69.00
Spread: 2.00 (2.985%)
Market Cap: £309.47m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20221:57 pmRNSIssue of Equity and Total Voting Rights
8th Apr 20227:00 amRNSAffyXell partners with Biocytogen and KNTSC
7th Apr 20224:31 pmRNSIssue of Equity and Total Voting Rights
6th Apr 20227:00 amRNSPreliminary Results
30th Mar 20224:41 pmRNSSecond Price Monitoring Extn
30th Mar 20224:35 pmRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSNotice of Results and Investor Presentation
29th Mar 20227:00 amRNSAVA6000 data poster presentation at AACR
21st Mar 20227:00 amRNSDirectorate Change
16th Mar 20227:00 amRNSVimian acquires Avacta’s Animal Health Division
14th Feb 20224:41 pmRNSSecond Price Monitoring Extn
14th Feb 20224:36 pmRNSPrice Monitoring Extension
7th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20225:26 pmRNSIssue of Equity and Total Voting Rights
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSDose escalation in the phase I trial of AVA6000
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:36 pmRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSSecond pre|CISION Pro-drug Candidate Selected
12th Jan 20222:05 pmRNSSecond Price Monitoring Extn
12th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSUpdate on AffiDX and detection of Omicron variant
4th Jan 202211:06 amRNSSecond Price Monitoring Extn
4th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Dec 20214:26 pmRNSIssue of Equity and Total Voting Rights
22nd Dec 202111:05 amRNSSecond Price Monitoring Extn
22nd Dec 202111:00 amRNSPrice Monitoring Extension
22nd Dec 20217:00 amRNSAffiDX Receives CE Mark for Consumer Self-Testing
16th Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
15th Dec 20217:00 amRNSAffiDx® lateral flow test detects Omicron variant
15th Dec 20217:00 amRNSChange of auditor
29th Nov 20217:00 amRNSFDA Approval of IND Application for AVA6000
18th Nov 20214:41 pmRNSSecond Price Monitoring Extn
18th Nov 20214:36 pmRNSPrice Monitoring Extension
2nd Nov 20217:00 amRNSUpdate on UK Availability of AffiDX Test
14th Oct 20214:36 pmRNSPrice Monitoring Extension
14th Oct 202112:36 pmRNSIssue of Equity and Total Voting Rights
30th Sep 20217:00 amRNSInterim Results for the Period Ended 30 June 2021
29th Sep 20217:00 amRNSDevelopment Milestone in LG Chem Partnership
9th Sep 20217:00 amRNSNotice of Results
2nd Sep 20217:00 amRNSAppointment of Chief Scientific Officer
25th Aug 20214:40 pmRNSSecond Price Monitoring Extn
25th Aug 20214:35 pmRNSPrice Monitoring Extension
18th Aug 20217:00 amRNSDirectorate Change
11th Aug 20217:00 amRNSFirst Patient Dosed in AVA6000 Phase 1 Trial
4th Aug 20217:00 amRNSUpdate on AffiDX Lateral Flow Test
14th Jul 20217:00 amRNSDiagnostics achieves ISO 13485 Certification
12th Jul 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.